Clinical Trials Logo

Clinical Trial Summary

Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis


Clinical Trial Description

Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the use of 2% Ganciclovir Eye Drops, its potential risks and benefits. This is a monocencer, single arm, prospective study. The experimental group is: 2% Ganciclovir Eye Drops therapy group. Administration method and dose adjustment: 2% ganciclovir eye drops, 10 times / day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than six weeks. According to best corrected visual acuity (BCVA), intraocular pressure, corneal abrasion, anterior chamber and vitreous inflammation, optical coherence tomography (OCT), Ultra wide angle fundus image and so on. The investigators evaluate the effects of 2% Ganciclovir Eye Drops in treatment of cytomegalovirus retinitis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05911503
Study type Interventional
Source Tianjin Medical University
Contact xiaomin Zhang
Phone +8613920023990
Email xiaomzh@126.com
Status Recruiting
Phase Early Phase 1
Start date July 1, 2023
Completion date June 30, 2027

See also
  Status Clinical Trial Phase
Completed NCT00000135 - Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) Phase 2/Phase 3
Completed NCT00000118 - Ganciclovir Implant Study for Cytomegalovirus Retinitis Phase 3
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT00000143 - Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Phase 3
Completed NCT01866397 - Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Phase 4
Completed NCT00004794 - Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Phase 2
Completed NCT00000136 - Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) Phase 3
Completed NCT00091884 - Efficacy of Elevated CD4 Counts on CMV Retinitis N/A
Completed NCT00002377 - A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Phase 3
Completed NCT00001611 - Immune Activity Against CVM Retinitis N/A
Completed NCT00000134 - Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Phase 3
Completed NCT00000168 - Longitudinal Study of Ocular Complications of AIDS (LSOCA) N/A
Completed NCT04831333 - Deep Learning-based System and AIDS-related Cytomegalovirus Retinitis
Active, not recruiting NCT00002384 - A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS N/A
Active, not recruiting NCT00002301 - A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir N/A
Active, not recruiting NCT00017784 - Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Phase 3
Completed NCT00000673 - A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy Phase 1
Completed NCT00002330 - A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS N/A
Completed NCT00002070 - Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Phase 3
Withdrawn NCT00000697 - A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir Phase 2